Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,671 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05229003RecruitingPhase 2
Irinotecan, anlotinib, and pembrolizumab-like drug for advanced colon cancer
This Phase 2 study tests adding anlotinib and penpulimab to irinotecan for colorectal cancer that has come back or spread after earlier chemotherapy. It may help shrink tumors and control the disease when standard first-line treatment no longer works.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT05272696RecruitingPhase 2
Pembrolizumab plus chemo before treatment for advanced head and neck cancer
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
Guangzhou, GuangdongAges 18–70 - NCT05327023RecruitingPhase 1/Phase 2
Donor immune cells after bone marrow transplant for high-risk blood cancers
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
Bethesda, MarylandAges 12–120 - NCT05343325RecruitingPhase 2
Neoadjuvant low-dose radiation with chemo-immunotherapy for head and neck cancer
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
Zhuhai, GuangdongAges 18–70 - NCT05381792Recruiting
Test of gut bacteria changes after colon tumor removal
This study looks at how the gut’s bacteria and bacterial gene signals change after doctors remove certain advanced growths in the colon using endoscopy. If you need an endoscopic procedure for an advanced adenoma or early colon cancer, your stool/bacteria samples may help researchers understand what changes after treatment.
Shatin, New TerritoriesAges 18–90 - NCT05406856Recruiting
Adaptive proton therapy for cervical cancer with chemo
This trial tests whether an “adaptive” type of radiation planning using proton therapy and MRI-guided brachytherapy can improve treatment for people with cervical cancer. It aims to deliver curative treatment more precisely while still combining it with chemotherapy (cisplatin) when appropriate.
LeidenAges 18 years+ - NCT05405673Recruiting
Test stool or tissue genes to find advanced colon growth
This study checks how well a set of bacterial gene markers (a DNA-like test) can help identify advanced “precancer-like” or higher-risk growths in the colon. It may help doctors better target who needs closer follow-up during colonoscopy.
Hong KongAges 18 years+ - NCT05410977Recruiting
Testing blood and stool for colon cancer in Lynch syndrome
This study collects blood and stool samples to see how well they can detect colorectal cancer or advanced growths in people with Lynch syndrome (an inherited colon cancer risk) or suspected Lynch syndrome. It may help find cancer or precancer earlier, which can improve next-step decisions.
Scottsdale, ArizonaAges 18 years+ - NCT05412589RecruitingPhase 2
Testing three cancer medicines for advanced liver cancer
This trial studies how well a combination of chemotherapy, immunotherapy, and an anti-angiogenesis medicine works for advanced hepatocellular carcinoma (HCC), a type of liver cancer. It may help slow tumor growth and improve outcomes by attacking cancer in different ways.
Guangzhou, GuangdongAges 18–75 - NCT05440708RecruitingPhase 1/Phase 2
Study drug for advanced liver cancer that cannot be removed
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
Birmingham, AlabamaAges 18 years+ - NCT05446467RecruitingPhase 2
Pembrolizumab before surgery for advanced head and neck cancer
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
Qingdao, ShandongAges 18–85 - NCT05479409RecruitingPhase 2
Radiation before surgery for advanced breast cancer
This trial tests whether giving radiation therapy before surgery helps people with locally advanced breast cancer that hasn't been removed with chemotherapy. It may offer a new option for those who cannot have surgery right away.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05488548RecruitingPhase 1
Study drug that blocks BET and CBP/p300 in advanced cancers
This Phase 1 trial tests an investigational medicine that targets BET and CBP/p300 to try to slow or control advanced, hard-to-treat cancers. You may be eligible if you have certain prostate cancer or NUT midline carcinoma, or specific blood cancers like CMML or myelofibrosis (MF), and your body functions are strong enough for chemotherapy-style treatment.
Phoenix, ArizonaAges 18 years+ - NCT05507411RecruitingPhase 2
Watch-and-wait after chemo-radiation plus immunotherapy for esophagus cancer
This Phase 2 study tests whether adding an immunotherapy drug (camrelizumab) to standard chemo-radiation can help some people with operable esophagus cancer avoid immediate surgery, using a “watch and wait” approach. If it works, it may reduce the need for early surgery for carefully selected patients.
Hanzhou, ZhejiangAges 18–75 - NCT05523947RecruitingPhase 1/Phase 2
Study drug for HER2-positive solid tumors, with dose changes
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Boston, MassachusettsAges 18 years+ - NCT05528055RecruitingPhase 1
Safety study of SCR-6920 for advanced cancers
This Phase 1 trial tests whether SCR-6920 capsules are safe and tolerable in people with advanced, treatment-resistant cancers. It may help doctors learn the right way to dose the medicine and check for side effects.
Jinan, ShandongAges 18–75 - NCT05584761RecruitingPhase 1/Phase 2
Cord blood stem cells plus azacitidine for advanced blood cancers
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
Nanjing, JiangsuAges 18–80 - NCT05600127RecruitingPhase 2
Chemotherapy then immunotherapy plus surgery for advanced bladder cancer
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT05608200RecruitingPhase 3
Lenvatinib plus immunotherapy with TACE versus standard TACE
This study compares a stronger treatment plan (lenvatinib plus sintilimab plus TACE) against a standard plan (lenvatinib plus TACE) for advanced liver cancer. It aims to see which plan works better to control tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT05615818RecruitingPhase 3
Study of targeted drug choices for advanced bile duct cancers
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
BrusselsAges 18 years+ - NCT05628922RecruitingPhase 2
Blood EBV DNA–guided therapy for advanced nasopharyngeal cancer
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05636618RecruitingPhase 1/Phase 2
Targeted radiation for certain receptor-positive tumors
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Jacksonville, FloridaAges 18–90
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,671 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.